Baird served as co-manager on this offering
AboutConstellation Pharmaceuticals, Inc. (“Constellation” or the “Company”) (NASDAQ-GS:CNST) recently completed an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $35.00 per share, for total gross proceeds of $192.5 million. In addition, Constellation has granted the underwriters a 30-day option to purchase up to 825,000 additional shares of its common stock at the public offering price, less the underwriting discount and commissions.
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates. Constellation Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
CONTACT US TO LEARN MORE
- June 2020
- Constellation Pharmaceuticals, Inc.
- Target Location
- North America